Possible approaches towards improving the poor results of the chemotherapy of gut cancer may be considered under two headings: clinical and experimental. Clinically it might be helpful if cases were studied at special centres, as advocated by York Mason (1973) , where techniques such as radioisotope scanning, lymphography and monitoring of tumour index substances could be carried out. This would facilitate accurate staging of the disease, and enable the various stages to be correlated with therapeutic response, so forming a base-line against which new agents might be tested clinically. One such system has been described at the Memorial Sloan-Kettering Cancer Center, New York (Young et al. 1960 ).
Since 5-fluorouracil (5-FU) is the only drug which produces a consistent response, it should always be considered provided it is given optimally, i.e. as a single intravenous injection once every week or two weeks. There are valid reasons, theoretical (Bruce et al. 1966 ) and practical (Jacobs et al. 1971) , for this dose schedule. The practice of giving the drug daily for several days or until toxicity supervenes should be abandoned; it has no therapeutic advantage and often makes the patient worse than he would be without treatment. In bad-risk cases it is logical to start the drug when the number of malignant cells is smallest, i.e. immediately after surgery.
Even if these suggestions were adopted, however, 80 % of patients with inoperable gut cancer would fail to respond to drug therapy now available.
Since giving combinations of existing agents does not appear to improve results, the overriding need in gut cancer is for newer and more effective drugs, and the basic question therefore is how such drugs may be developed. Experimentally, it is important to discover what agents kill resistant cells. There are at least two systems which may be helpful. The first, used by Dr Leon Cobb in Professor A M Neville's department at the Chester Beatty Research Institute, and also at other centres, involves taking the tumour from the patient at operation and transplanting it into immunologically deprived mice (L M Cobb 1973, personal communication). The tumour grows in such animals, and has the same histological features and mitotic index as the original tumour. It can be retransplanted into successive generations of thymectomized or irradiated mice. New agents could easily be screened in this approximation system. Another way of finding out whether resistant cells can be killed is to use a line of cells in tissue culture which are resistant to 5-FU. This sytem is simple to use and could screen new agents very rapidly.
Intracellular studies on the 'how' and 'why' of cell death, such as disturbances in nucleotide pools, &c., have been under way for at least fifteen years and have made no contribution to any practical clinical problem. Even if such studies are carried out on histologically and kinetically heterogeneous human tumour cells, I think they are unlikely to be helpful for many years.
It seems to me that improvements in the chemotherapy of gut cancer, as with other tumours, are most likely to occur gradually and empirically by testing new agents in patients. Drugs of suggestive clinical value at present are CCNU (a nitrosourea), VM26 (a podophyllin derivative) and possibly 5-azacytidine (a derivative of cytosine arabinoside). Finally, although gut cancer occurs twice as commonly as the leukemias and lymphomas put together, it attracts only one-tenth as many research contributions. Perhaps progress would be quicker if more people worked on the problem. Dr George Crile jr (Department ofGeneral Surgery, Cleveland Clinic Center, 9500 EuclidAvenue, Cleveland, Ohio 44106, USA)
Changing Concepts in the Management of Cancer
One of the central dogmas of cancer surgery has been the belief that cancers should be treated initially by radical resection of the primary tumour and the regional nodes. In recent years, however, in treating external cancers such as melanomas and cancers of the mouth, breast and lower rectum, some surgeons have had success with graded approaches, in which the primary tumour is removed or destroyed and the area of lymph drainage is left undisturbed unless evidence ofmetastasis appears.
Graded operations have two advantages, one practical, the other theoretical: (1) in many cases, nodes are not involved and the necessity of a mutilating operation is avoided; (2) in animal models, and perhaps also in human cancer, there is mounting evidence that removal, or irradiation, of regional nodes weakens the immunologic resistance of the host, thereby hastening the spread and growth of metastases.
In operations for low-lying cancers of the rectum there is a double advantage to local treatment, such as by electrocoagulation: (1) the mortality rate of the operation is nearly nil compared to 2-15 % for combined abdominoperineal resection; (2) colostomy is avoided.
Since nodes are involved in only 30% of lowlying rectal cancers suitable for local treatment and since only one patient in 5 whose nodes are involved is cured by resection, it is clear that, in cases in which the local tumour can be destroyed, only 6 % more patients would be cured by resection than by coagulation. Since the operative mortality of resection is immediate and that from cancer in nodes is delayed, one can calculate that, in terms of years of survival, a surgeon cannot afford to resect unless his operative mortality is less than 3%, and this takes no account of the disadvantages of colostomy or of the possibility of palpating involved nodes and removing them at a secondary operation.
It appears to us (Crile & Turnbull 1972) that small and medium-sized rectal cancers, especially if they protrude into the bowel instead of ulcerating deeply, should be treated locally by coagulation. This eradicates the tumour in more than 80% of cases and, when it fails, the rectum can still be resected with just as high a rate of survival as if it had been done at first. REFERENCE Crile G jr & Turnbull R B (1972) Surgery, Gynecology and Obstetrics 135, 391-396 
